Sanofi pasteur

Sanofi pasteur is the vaccine division of sanofi-aventis Group. It is the largest company in the world devoted entirely to vaccines.

History
In 2004, Aventis merged with and into Sanofi. The new sanofi-aventis Group became the world's 3rd largest pharmaceutical company. Aventis Pasteur, the vaccine division of sanofi-aventis Group, changes its name to sanofi pasteur.

Key Dates

 * 1897, Marcel Mérieux creates the Mérieux Biological Institute in Lyon. Richard Slee creates the Pocono Biological Laboratories, in Swiftwater (Pennsylvania) in the US
 * 1914, John FitzGerald creates Connaught Laboratories, part of the University of Toronto.
 * 1968, Rhône-Poulenc acquires 51% of the capital of the Institut Mérieux.
 * 1974, Pasteur Institute creates Pasteur Production, a subsidiary specializing in manufacturing vaccines
 * 1978, Connaught Laboratories in Canada acquires the vaccine manufacturing facility (Merrell-National Laboratories) at Swiftwater, Pennsylvania, US.
 * 1985, Pasteur Production, the vaccines branch of the Institut Pasteur, is acquired by the Mérieux Institute, and Pasteur Vaccins is created
 * 1989, The Mérieux Institute acquires the Connaught Laboratories in Canada and its subsidiaries and becomes a world leader in human biology
 * 1990, Creation of Pasteur Mérieux Serums & Vaccins
 * 1994, Pasteur Mérieux Sérums & Vaccins becomes a wholly owned subsidiary of Rhône-Poulenc.
 * 1996, Pasteur Mérieux Connaught is the new name of Pasteur Mérieux Serums et Vaccins
 * 1999, Rhône-Poulenc and Hoechst unite their Life Sciences activities in a single company, which takes on the name Aventis. Within this group, Pasteur Mérieux Connaught changes its name to Aventis Pasteur.
 * 2004, merger of Aventis with and into Sanofi. The new sanofi-aventis Group becomes the world's 3rd largest pharmaceutical company, behind Pfizer and GlaxoSmithKline. Aventis Pasteur, the vaccine division of the sanofi-aventis Group, changes its name to sanofi pasteur.

Key facts & figures in 2004

 * Sanofi pasteur - proforma sales: € 1.624 billion (growth of 7.5%)
 * Staff: over 9,000 employees
 * Nearly a billion doses of vaccines sold to protect over 500 million people in the world
 * A wide range of vaccines protecting against 20 bacterial and viral diseases
 * A presence in 150 countries
 * R&D: 17% of sales reinvested in R&D, over 1,000 persons working in France, U.S.A. and Canada
 * Headquarters: Lyon, France

Vaccines

 * TheraCys - bladder cancer
 * ADACEL (Tdap) - diphtheria, tetanus and pertussis
 * DAPTACEL (DTaP) - diphtheria, tetanus and pertussis
 * Diphtheria and Tetanus Toxoids Adsorbed USP, diphtheria, tetanus and pertussis
 * Tetanus Toxoid Adsorbed - diphtheria, tetanus and pertussis
 * TriHIBit (DTaP/Hib Booster Use) - diphtheria, tetanus and pertussis and  haemophilus influenzae type b
 * Tripedia (DTaP vaccine) - diphtheria, tetanus, pertussis
 * ActHIB - haemophilus influenzae type b
 * Fluzone, Influenza Virus Vaccine - influenza
 * Fluzone, Influenza Virus Vaccine, No Preservative - influenza
 * Fluzone, Influenza Virus Vaccine, No Preservative: Ped Dose - influenza
 * Menactra - meningococcal
 * Menomune-A/C/Y/W-135 - meningococcal
 * IPOL - Polio
 * Imogam Rabies-HT - rabies immune globulin
 * IMOVAX RABIES - rabies
 * DECAVAC - tetanus and diphtheria
 * Tetanus Toxoid Adsorbed - tetanus
 * Tetanus Toxoid For Booster Use Only - tetanus
 * JE-VAX - Japanese encephalitis virus
 * Typhim Vi - typhoid fever
 * YF-VAX - yellow fever
 * Tubersol - tubercolosis